

Infertility

—

Brooke Rossi, MD
Adjunct Assistant Professor
Department of Obstetrics & Gynecology
Division of Endocrinology-Infertility
The Ohio State University Wexner Medical Center

MedNet21
Center for Continuing Medical Education

THE OHIO STATE UNIVERSITY
WEXNER MEDICAL CENTER

- ### Objectives
- Classify the different types of female and male infertility
 - Choose appropriate diagnostic tests based on history
 - Recognize limitations of each test and when further testing is necessary
 - Describe appropriate treatment

- ### Infertility: Definitions
- Failure to conceive with regular intercourse
 - < 35 yo: 12 months
 - ≥ 35 yo: 6 months
 - Inability to conceive on own or with partner
 - Type
 - Primary: No history of pregnancy
 - Secondary: History of pregnancy

Definitions of infertility and recurrent pregnancy loss: a committee opinion

Practice Committee of the American Society for Reproductive Medicine
American Society for Reproductive Medicine, Birmingham, Alabama

This document contains the definitions of infertility and recurrent pregnancy loss as defined by the Practice Committee of the American Society for Reproductive Medicine. It replaces the document, "Definitions of Infertility and Recurrent Pregnancy Loss: a Committee Opinion," first published in 2012 (Fertil Steril 2012;98(4):849-854). © 2015 by American Society for Reproductive Medicine. It remains available as a committee opinion.

Abstract: This committee opinion discusses the definitions of infertility and recurrent pregnancy loss. It includes a summary of the definitions of infertility and recurrent pregnancy loss as defined by the Practice Committee of the American Society for Reproductive Medicine. It also includes a summary of the definitions of recurrent pregnancy loss as defined by the Practice Committee of the American Society for Reproductive Medicine. The definitions of infertility and recurrent pregnancy loss are based on the definitions of the World Health Organization, the American Medical Association, the American Society for Human Reproduction and Embryology, the International Committee for Monitoring Assisted Reproductive Technologies (ICMART), and the American Society for Human Reproduction. The definitions of recurrent pregnancy loss are based on the definitions of the American Society for Human Reproduction and Embryology. The definitions of infertility and recurrent pregnancy loss are based on the definitions of the World Health Organization, the American Medical Association, the American Society for Human Reproduction and Embryology, the International Committee for Monitoring Assisted Reproductive Technologies (ICMART), and the American Society for Human Reproduction. The definitions of recurrent pregnancy loss are based on the definitions of the American Society for Human Reproduction and Embryology.

When should the evaluation begin?


- < 35 yo: 12 months
- 35-39 yo: 6 months
- ≥ 40 yo: Immediately
 - Age-related fertility decline, increase incidence of disorders that impair fertility, higher risk of pregnancy loss
- Evaluate sooner based on history
 - Oligo/amenorrhea, chemotherapy/radiation, endometriosis, tubal disease, male risk factors

Fertility

- What is needed to conceive?
 - Oocytes of good quality
 - Sperm of good quality and quantity
 - Patency of 1 tube
 - Normal uterine cavity




Ovarian follicular development



Infertility

- May have more than contributing factor



Infertility: Female history

- Duration of infertility, previous evaluation/ treatment
- Pregnancy history
- Menstrual history
- Previous contraception
- Coital frequency and sexual dysfunction
- Gynecologic history
- Medications

Infertility: Female history

- Chemotherapy, radiation
- Medical/ surgical history (especially pelvic and abdominal)
- Social history, environmental and occupational exposures
- Family history of birth defects, intellectual disability, or reproductive failure
- Details of intercourse including lubricants
- Exercise, dietary history

Infertility: Female history

- Chemotherapy, radiation
- Medical/ surgical history (especially pelvic and abdominal)
- Social history, environmental and occupational exposures
- Family history of birth defects, intellectual disability, or reproductive failure
- Details of intercourse including lubricants
- Exercise, dietary history

*How is the stress level?
How is the couple doing?
Are they supported?*

Diagnostic tests

- Assessment of:
 - Ovulation
 - Ovarian reserve
 - Tubal patency
 - Uterine cavity
- Preconception screening
 - Genetic carrier screening, immunization

Infertility tests that should not be routinely ordered, unless specifically indicated (33).

- Laparoscopy for unexplained infertility
- Advance sperm function testing (e.g., DNA fragmentation testing)
- Postcoital testing
- Thrombophilia testing
- Immunologic testing
- Karyotype
- Endometrial biopsy
- Prolactin
- Progesterone
- Estradiol
- Follicle-stimulating hormone
- Luteinizing hormone

ASRM. Fertility evaluation of infertile women. Fertil Steril 2021.

Diagnostic tests: Ovulation

- Ovulation
 - Menstrual history may be reliable
 - Mid-luteal “day 21” progesterone
 - Check 7 days post ovulation
 - >3 ng/mL defines ovulation
 - No “good” or “bad” level due to pulsatility

WHO Classification of anovulation

Class	Physiology	Clinical presentation	FSH	Estradiol
Class 1	Hypogonadotropic hypogonadism	Hypothalamic amenorrhea Hyperprolactinemia	Low	Low
Class 2	Normogonadotropic normoestrogenic	Polycystic ovary syndrome (PCOS)	Normal	Normal
Class 3	Hypergonadotropic hypoestrogenic	Primary ovarian insufficiency (POI)	High	Low

14

Diagnostic tests: Ovarian reserve


- Indications
 - > 35 years yo
 - Family history of POI
 - History of ovarian surgery, chemotherapy, pelvic radiation
 - Unexplained infertility
 - IVF
- Ovarian reserve testing
 - Day 3 FSH + estradiol, antral follicle count, CCCT
 - Normal: < FSH 10 IU/ mL, estradiol 80 pg/mL
 - Anti-mullerian hormone
- Only use for treatment planning and expectations
- Does not imply inability to conceive

ASRM. Fertil Steril.2020

Diagnostic tests: Tubal and uterine


- Tubal patency/ uterine cavity evaluation
- Hysterosalpingogram
 - Fluoroscopy with contrast
 - May be therapeutic
- Hysterosalpingo-contrast sonography
 - Ultrasound of uterus, tubes, adnexa before and after transcervical injection of echogenic contrast media
- Saline infusion sonohysterography/ flexible hysteroscopy if tubal patency not needed

Hysterosalpingogram



Male Evaluation

Testosterone Production and Spermatogenesis



Infertility: Male history

- Duration of infertility, prior evaluation or treatment
- Fertility in other relationships
- Medical/surgical history, testicular surgery/ injury, history of mumps
- Chemotherapy, radiation
- Medical/ surgical history
- Social history, environmental and occupational exposures
- Family history of birth defects
- Details of intercourse, lubricants
- Exercise, dietary history
- Sexual dysfunction


Diagnostic testing: Male

- Semen analysis
- Physical exam
 - Secondary sexual characteristics
 - Testicular volume
- Scrotal ultrasound
- Hormonal testing
 - Sperm count < 16 million
 - Serum total testosterone (between 8-10 AM), FSH, LH
 - TSH, prolactin

Semen analysis

- Home or in-office collection
- 2-3 days of abstinence
- May need to repeat if abnormal

- Useful if abnormal



Semen analysis: WHO 2021

Semen volume (ml)	1.4 (1.3-1.5)
Total sperm number (million)	39 (35-40)
Sperm concentration (million/ ml)	15-16
Total motility (%)	42 (40-43)
Progressive motility (%)	30 (29-31)
Normal forms (%)	4 (3.9-4)

Diagnostic testing: Male

- Chromosomal testing
 - Karyotype
 - Sperm concentration ≤ 10 million/mL
 - Klinefelter syndrome
 - Chromosomal translocations
 - Y-chromosome microdeletions
 - Sperm concentration ≤ 5 million/mL
- Cystic fibrosis transmembrane-conductance regulator (*CFTR*) mutations
 - Obstructive azoospermia with congenital absence of the vas deferens
 - Also test female partner

Male hormonal evaluation

Clinical condition	FSH	LH	Testosterone	Prolactin
Normal spermatogenesis	Normal	Normal	Normal	Normal
Hypogonadotropic hypogonadism	Low	Low	Low	Normal
Complete testicular failure/hypergonadotropic hypogonadism	High	High	Normal/low	Normal
Prolactin-secreting pituitary tumor	Normal/low	Normal/low	Low	High

Basic fertility evaluation

Female		
History		
Physical		
Pre-pregnancy evaluation		
Additional testing for cause of infertility	Diminished ovarian reserve	Day 2-4 FSH, estradiol Antimüllerian hormone (AMH) Antral follicle count by transvaginal ultrasound
	Ovulatory dysfunction	Luteal progesterone level
	Tubal factor	HSG, hysterosalpingo-contrast sonography
	Uterine factor	HSG, hysteroscopy, sonohysterography, transvaginal ultrasound
Male		
History		
Semen analysis		

ACOG Obstet Gynecol. 2019

- ### What can't you find?
- 10-20% have unexplained infertility!
 - Endometriosis
 - Laparoscopy
 - Pelvic adhesions
 - Laparoscopy
 - Issues with sperm function/ fertilization issues
 - In vitro fertilization
 - Implantation issues
 - No testing available
 - Egg quality
 - ? In vitro fertilization

- ### Infertility management and treatment
- Correction of life-style or coital practice
 - Ovulation induction
 - Intrauterine insemination
 - Hysteroscopy and/or laparoscopy
 - In vitro fertilization
 - 3rd party reproduction

Management: Lifestyle modification

- Functional hypothalamic amenorrhea
 - Reduce stress (exercise, activity)
- PCOS
 - Weight loss, exercise
 - Is there time considering age?
- Hyperprolactinemia
 - Ensure no other factor is increasing prolactin
- Environmental risks
 - Tobacco, alcohol, diet

29

Management: Oral agents

- Lead to increase in FSH and follicular development
- Lower risk of multiple gestation
- Low-cost, easy administration
- Clomiphene citrate
 - SERM
- Letrozole
 - Aromatase inhibitor
 - Off-label use
- Dopamine agonists

30

Management: Oral agents

- Clomiphene citrate/ letrozole
 - Low cost, 5 day course
 - Cumulative pregnancy rate 30-40%
- Risks
 - Twins 7-9%, triplets <1%
 - Mild side effects
- Can be paired with intercourse or insemination
- Letrozole recommended for PCOS

Management: Gonadotropins

- Increase FSH concentration to exceed threshold to recruit follicles
- Recombinant FSH
- Human menopausal gonadotropins (hMG) (FSH+LH)
 - Needed for both folliculogenesis and steroidogenesis
 - Hypogonadotropic hypogonadism
- Indications
 - PCOS resistant to other treatments
 - Hypogonadotropic hypogonadism
 - Controlled ovarian hyperstimulation

32

Management: Gonadotropins

- Outcomes
 - Pregnancy rate 15-25%/cycle
- Risks
 - Multiple gestation
 - Responsible most high order multiple gestation among all treatments
 - 5% triplets or more
 - Ovarian hyperstimulation syndrome
 - Costly
- No increased risk of cancer, birth defects, SAB


33

Management: Hyperprolactinemia

- Dopamine agonists
 - Bromocriptine
 - Side-effects likely
 - Cabergoline
- High chance of ovulation and pregnancy once PRL falls
- Stop when patient conceives


34

IVF: Controlled ovarian hyperstimulation




IVF: Oocyte retrieval and embryo transfer


- Transvaginal retrieval
- Fertilization and embryo culture in the laboratory
- Embryo transfer, embryo biopsy, and/or embryo freeze



Intracytoplasmic sperm injection (ICSI)



Embryo development to blastocyst




Who needs IVF/ICSI?

- Tubal factor infertility
- Severe male factor infertility
- Failed other fertility treatments
 - Unexplained infertility
 - Endometriosis
 - Decreased ovarian reserve
 - Recurrent pregnancy loss
- Patients with genetic mutations who want to avoid passing on mutations to child
- Fertility preservation
 - Oocytes or embryos

Current trends in ART

- Blastocyst culture
- Reduction of OHSS
 - GnRH antagonist cycles with GnRH agonist trigger
- Preimplantation genetic testing (PGT)
- Elective single embryo transfer (eSET)
- Freeze-all cycles
- Increasing oocyte cryopreservation



Preimplantation genetic testing (PGT)

- PGT-A
 - Aneuploidy (trisomy 21, trisomy 18, etc.)
- PGT-M
 - Monogenetic disease (cystic fibrosis, SMA)
 - Recessive, dominant, x-linked
- PGT-SR
 - Balanced translocation

Embryo biopsy for PGT



PGT: Indications

- Increased risk of having a child with a genetic condition
- Avoiding a sex-linked genetic condition
- Have a child that is a HLA type match for a sibling needing stem cell therapy
- Avoid pregnancy loss if patient/ partner has a balanced translocation
- Older patients requesting single embryo to be transferred

Summary

- Initiation of the infertility evaluation is based on age and history
- History is key
- About 20-30% of couples will have normal testing
- Treatment may include correction or bypass of medical issue
- Most patients, in time, will be successful

References and Guidelines

- Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. *N Engl J Med* 2007;356:551-566.
- Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. *NICHD Reproductive Medicine Network. N Engl J Med* 2014;371:119–29
- Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in infertile women: a committee opinion. *Fertil Steril.* 2013 Aug;100(2):341-8.
- Practice Committee of American Society for Reproductive Medicine. Use of exogenous gonadotropins in anovulatory women: a technical bulletin. *Fertil Steril.* 2008 Nov;90(5 Suppl):S7-12
- Practice Committee of American Society for Reproductive Medicine. Role of metformin for OI in infertile patients with polycystic ovary syndrome(PCOS): a guideline. *Fertil Steril.*2017 Sep;108(3):426-441.
- ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome. *Obstet Gynecol.* 2018 Jun;131(6):e157-e171.

45

References and Guidelines

- Female age-related fertility decline. Committee Opinion No. 589. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice and Practice Committee. *Fertil Steril.*2014 Mar;101(3):633-4.
- Definitions of infertility and recurrent pregnancy loss: a committee opinion. Practice Committee of American Society for Reproductive Medicine. *Fertil Steril.* 2013 Jan;99(1):63
- Diagnostic evaluation of the infertile male: a committee opinion. Practice Committee of American Society for Reproductive Medicine. *Fertil Steril.* 2012 Aug;98(2):294-301.
- Diagnostic evaluation of the infertile female: a committee opinion. Practice Committee of American Society for Reproductive Medicine. *Fertil Steril.* 2012 Aug;98(2):302-7.